A study to investigate the effect on QTcF of Baxdrostat compared with placebo, using Moxifloxacin as a positive control, in healthy participants

Exclusion Criteria

• • History of any clinically significant disease or disorder.
• • History or presence of gastrointestinal, hepatic, or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
• • History of additional risk factors for Torsade de Pointes.
• • History of neoplastic disease.
• • Family history of sudden cardiac death.
• • Any skin condition likely to interfere with ECG electrode placement or adhesion.
• • Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of drug.
• • Any clinically significant abnormalities at screening and first admission in rhythm, conduction, or morphology of the 12-lead resting ECG and any clinically important abnormalities in the 12-lead ECG as considered by the investigator.
• • Participant has clinical signs and symptoms consistent with COVID-19.
• • Current smokers or those who have smoked or used nicotine products (including e-cigarettes) within the 3 months prior to screening.
• • Positive screen for drugs of abuse, alcohol or cotinine at screening or on each admission to the Clinical Unit.
• • Participants who have previously received Baxdrostat.
• • Participants with any special dietary restrictions such as participants who are lactose intolerant or are vegetarians/vegans.
• • Participants who cannot communicate reliably with the investigator and/or are not able to read, speak, and understand the local language.
• • Vulnerable participants, eg, kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.